Sartorius Stedim Biotech S.A. provided earnings guidance for the fiscal year 2022. The company expects consolidated sales revenue growth is now expected to be in the lower half of the range of around 15% to 19% projected so far, with non-organic growth from acquisitions anticipated to contribute about 2% points.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
192.6 EUR | +0.21% | -2.16% | -19.60% |
16/05 | Sartorius sinks again towards year low | DP |
16/05 | Transcript : Sartorius Stedim Biotech S.A., Sartorius Aktiengesellschaft - Analyst/Investor Day |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.60% | 20.34B | |
-5.56% | 181B | |
-0.11% | 108B | |
-6.17% | 66.12B | |
+2.64% | 50.65B | |
+6.58% | 43.66B | |
+4.91% | 41.3B | |
+21.98% | 31.6B | |
+14.45% | 25.03B | |
-5.81% | 24.16B |
- Stock Market
- Equities
- DIM Stock
- News Sartorius Stedim Biotech
- Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2022